Autologous dendritic cell therapy (DC therapy)

Autologous dendritic cell therapy is a personalized immunotherapy modality that utilizes a patient's own immune cells to orchestrate a targeted response against specific diseases, primarily malignancies. Dendritic cells (DCs) are the most potent antigen-presenting cells in the human body, serving as the critical link between innate and adaptive immunity by processing and presenting antigens to T cells (Banchereau & Steinman, 1998). In this therapeutic approach, precursor cells are harvested via leukapheresis, differentiated into mature DCs, and 'pulsed' with specific antigens or transfected with genetic material ex vivo before being re-infused into the patient (Anguille et al., 2014). This process bypasses the immune-suppressive environment often created by tumors, allowing for the robust activation of tumor-specific cytotoxic T lymphocytes. While Sipuleucel-T is the most well-known FDA-approved example for treating prostate cancer, the field encompasses a wide range of experimental vaccines targeting various solid tumors and infectious agents (Kantoff et al., 2010). Because this entry describes a complex cellular therapeutic process rather than a single protein or receptor, it does not possess a discrete molecular drug target.

Other names

Dendritic cell vaccineDC-based immunotherapyAutologous dendritic cell vaccineAntigen-presenting cell therapySipuleucel-T (related modality)

Autologous dendritic cells are isolated from a patient's peripheral blood, matured and loaded ex vivo with specific antigens (such as tumor-associated antigens), and then re-administered to the patient. These cells migrate to lymphoid organs where they present the antigens to naive T cells via MHC class I and II molecules, inducing a targeted cytotoxic T lymphocyte (CTL) response and helper T cell activation against the specific disease-associated antigens (Banchereau & Steinman, 1998; Kantoff et al., 2010).